Lake:
Not sure it is that clear. Imagine the sales required by eVU to reach an EBITDA of say $1M. I think it will take $20M in eVU sales to reach that point. This is EPS of .0036. At a PE of 30 this is a share price of 0.10. It may take 10X the sales to get 10X the EBITDA to get to $1.00 per share. What may improve that is the revs from licensing. But as you can see from PTSC, that is almost a cash on hand per share valuation.
PTSC has bigger licensing potential.......and will likely succeed or fail depending on their acquisition/merger.
EDIG may get into healthcare or leisure apps of the eVU.........but it is not clear how they get to $100M in revs with $10M in net income let alone higher numbers to support sh price over a dollar.
In summary I think potential for shareholders is greater on EDIG at $0.15 than on PTSC at $0.40 due to the momentum play coming within 6 to 9 months for EDIG. That momo play got PTSC to $2.20. Just be wary........as a retracement is likely for EDIG too.
JMHO
biomedman........long since 99
